)
Beam Therapeutics (BEAM) investor relations material
Beam Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Editing platform
Base editing uses RNA-guided Cas9 targeting without double-stranded DNA breaks; attached deaminase enzymes enable A-to-G or C-to-T changes.
Four programs are in clinical development, spanning ex vivo sickle cell treatment and in vivo LNP-based editing for liver diseases.
Risto-cel for sickle cell disease
BEACON met all primary and secondary efficacy and safety endpoints; a BLA filing is targeted as early as year-end 2026.
Risto-cel showed the highest reported hemoglobin F, reduced hemoglobin S below 40%, normalized hemoglobin, and reduced blood viscosity.
Automated manufacturing supports reliable dosing; median mobilization was one, with the vast majority of trial participants requiring two or fewer mobilizations.
Dose is 3.5 million cells/kg; base editing requires fewer starting cells, while faster neutrophil engraftment may reduce infection risk and hospital stays.
In vivo programs
BEAM-302 for alpha-1 antitrypsin deficiency is in pivotal phase; FDA agreement supports accelerated approval, with pivotal completion expected in H1 2027.
At 60 mg, all patients reached the 11-micromolar total AAT threshold or higher; the FDA viewed the biomarker dataset as approvable for accelerated approval.
BEAM-301 for G6PC R83C showed two patients at 40 mg fasting for 15 hours versus a prior maximum of two hours; dose escalation is proceeding to 60 mg.
One BEAM-301 participant responded less, with compound heterozygosity and BMI 53 cited as possible factors; lower-dose participants are expected eventually to receive the optimal biological dose, without a timeline.
- Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable, precise base editing shows strong efficacy and safety, advancing toward commercialization.BEAM
Wells Fargo 21st Annual Healthcare Conference - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update - BEAM-304 base editing platform shows promise for durable PKU correction and broad patient coverage.BEAM
Conference presentation
Next Beam Therapeutics earnings date
Next Beam Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)